BridgeBio Oncology Therapeutics, Inc. BBOT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -182.11M | -154.10M | -134.04M | -114.93M | -- |
| Total Depreciation and Amortization | 752.00K | 742.00K | 610.00K | 468.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.11M | 15.96M | 13.11M | 10.45M | -- |
| Change in Net Operating Assets | 6.97M | 7.18M | 6.43M | 17.32M | -- |
| Cash from Operations | -151.28M | -130.21M | -113.89M | -86.70M | -- |
| Capital Expenditure | -284.00K | -468.00K | -606.00K | -543.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -191.07M | -226.98M | 73.93M | 91.66M | -- |
| Cash from Investing | -191.36M | -227.45M | 73.33M | 91.12M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 373.96M | 373.92M | 373.50M | 373.51M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 22.22M | 22.22M | 22.22M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.77M | -12.04M | -12.32M | -11.69M | -- |
| Cash from Financing | 365.18M | 384.10M | 383.40M | 384.04M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.55M | 26.44M | 342.84M | 388.46M | -- |